If you're a stockholder of Myriad Genetics (MYGN) you're probably feeling a little queasy right now and wondering why the stock is now falling fast after initially reacting positively to Thursday's Supreme Court Decision. After all, the ruling in Association for Molecular Pathology v. Myriad Genetics Inc. was exactly what most observers and analysts expected. A reasonable investor would think that this outcome would already be factored into the stock price, but most analysts were sticking to their outperform ratings on the stock after the decision, only to reverse course and downgrade the stock after it fell in Thursday and Friday's sessions.
So what went wrong? Where was the disconnect between what the Street expected and what actually...
Only subscribers can access this article, which is part of the PRO research library covering 3,768 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: